By combining IMG-1 and its proprietary culture and methods into a scalable and repeatable platform, Imagine Pharma has successfully regenerated and propagated billions of keratinocytes, enterocytes, islets, endothelial and pneumocyte cells. These cells can be used to replenish existing body supplies through transplantation or as the cornerstone for novel topical or oral therapeutics.
| Program | Discovery | Pre-Clinical | Phase 1 | |
|---|---|---|---|---|
| Regenerative Medicine | AIPC | |||
| T1 Diabetes Autologous Transplant | ||||
| Key | 2021-2022 | 2022-2023 |
|---|
The combination of Imagine’s IMG-1 and its proprietary culture and methods have shown the regeneration and propagation of safe insulin producing human islet cells (AIPCs). These islet cells can be safely scaled in the billions in short periods of time.
The foundation of the three platforms forms the basis of a multi-year scientific inquiry which will lead to many discoveries and potential therapies to increase the number of patients that can benefit from our transformative first-in-class treatments. With research programs targeting areas where there are currently no treatments and current approaches are not cost effective or have failed, Imagine is pushing the boundaries of what is possible.
We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.
| R & D Engine | Discovery | Pre-Clinical | Phase 1 |
|---|---|---|---|
| 2nd Generation Oral Delivery System | |||
| Additional Oral Biologics | |||
| Comprehensive Lung Healing Initiative | |||
| Comprehensive Bowel Initiative | |||
| Personalized Blood Vessel |
|||
If there are important updates to our pipeline or research, you can be the first to hear about them.
Read the latest news, announcements, and more in the Imagine Pharma newsroom.
Our team has decades of drug discovery and development experience in the industry and are working to bring to market transformative first-in-class treatments.
Get to know the team committed to developing innovative treatments for patients.